Not Signed In -
Travoprost |
Travatan |
Clinical Trial: Mechanism of Action of TRAVATAN 0.004% in Subjects with Glaucoma or Ocular Hypertension
This study is currently recruiting patients.
|
Purpose
The primary objective of this study is to describe the effect of TRAVATAN 0.004% Ophthalmic Solution on aqueous humor dynamics in subjects with a clinical diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Glaucoma Ocular Hypertension | Drug: Travoprost | Phase IV |
MedlinePlus related topics: Eye Diseases; Glaucoma
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Double-Masked, Placebo-Controlled, Paired Comparison Study of the Mechanism of Action of TRAVATAN 0.004% in Subjects with Glaucoma or Ocular Hypertension
Further Study Details:
Study start: April 2003
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
- Subjects 18 years of age or older
- of either sex
- of any race
- diagnosed with ocular hypertension or open angle glaucoma
Location and Contact Information
Alcon Call Center Alcon Representative (888)451-3937 (EYES) alconlabs.com
Nebraska
Alcon Call Center, Call for Details, Nebraska, United States; Recruiting
Alcon Representative 888-451-3937
More Information
Study ID Numbers: C-01-55
Record last reviewed: May 2003
Last Updated: October 13, 2004
Record first received: May 28, 2003
ClinicalTrials.gov Identifier: NCT00061503
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: May 2003
Last Updated: October 13, 2004
Record first received: May 28, 2003
ClinicalTrials.gov Identifier: NCT00061503
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Travatan (Drug Digest)
- Travatan Consumer Information (U.S. Food and Drug Administration)
email this page
print this page
bookmark this page
feedback on this page
